Literature DB >> 15139785

Reversal of chronic obstructive pulmonary disease-associated weight loss : are there pharmacological treatment options?

Jean K Berry1, Charles Baum.   

Abstract

Poor nutritional status is associated with an increased incidence of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). While a number of factors have been shown to produce tissue catabolism, no single mechanism has been clearly identified as a primary cause for weight loss in patients with severe COPD. Without a clear understanding of the aetiology of weight loss, therapeutic strategies to reverse this process have historically been unsuccessful. A review of recent studies allows consideration of a model of mechanisms of weight loss. This model includes multiple pathways that may be activated singly or simultaneously to cause loss of weight, specifically lean body mass. These include energy imbalances, elevated levels of cytokines, tissue hypoxia and the effects of cocorticosteroid therapy. To date, interventional studies that have looked at newer pharmacotherapies such as growth hormone and anabolic steroids in patients with COPD who are losing weight have not demonstrated reversal of weight loss or improvement in nutritional status. Currently, early identification of patients at risk for weight loss and aggressive nutritional supplementation coupled with an exercise programme has demonstrated the greatest benefit. However, with increasing understanding of the mechanisms that may be implicated, new targets for therapies are being identified. Of particular research interest are molecules such as leukotrienes, hormones, tumour necrosis factor-alpha and acute-phase proteins, which are noted to be elevated in some patients with COPD-associated weight loss. Currently, inhibitors to some of these inflammatory substances are used therapeutically in other chronic illnesses such as rheumatoid arthritis and cancer cachexia. Future research may investigate their usefulness in COPD and direct new therapies that target the processes contributing to weight loss in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139785     DOI: 10.2165/00003495-200464100-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  62 in total

Review 1.  Growth hormone therapy for protein catabolism.

Authors:  R C Jenkins; R J Ross
Journal:  QJM       Date:  1996-11

Review 2.  Role of polyunsaturated fatty acids in lung disease.

Authors:  J Schwartz
Journal:  Am J Clin Nutr       Date:  2000-01       Impact factor: 7.045

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Interactive effects of emphysema and malnutrition on diaphragm structure and function.

Authors:  M I Lewis; S A Monn; W Z Zhan; G C Sieck
Journal:  J Appl Physiol (1985)       Date:  1994-08

5.  Decreased alveolar oxygen induces lung inflammation.

Authors:  C Madjdpour; U R Jewell; S Kneller; U Ziegler; R Schwendener; C Booy; L Kläusli; T Pasch; R C Schimmer; B Beck-Schimmer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-10-11       Impact factor: 5.464

6.  Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study.

Authors:  L Burdet; B de Muralt; Y Schutz; C Pichard; J W Fitting
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

Review 7.  The pulmonary cachexia syndrome: aspects of energy balance.

Authors:  J Congleton
Journal:  Proc Nutr Soc       Date:  1999-05       Impact factor: 6.297

8.  Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease.

Authors:  Harry R Gosker; Mariëlle P K J Engelen; Henk van Mameren; Paul J van Dijk; Ger J van der Vusse; Emiel F M Wouters; Annemie M W J Schols
Journal:  Am J Clin Nutr       Date:  2002-07       Impact factor: 7.045

9.  Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery.

Authors:  H C Ward; D Halliday; A J Sim
Journal:  Ann Surg       Date:  1987-07       Impact factor: 12.969

10.  Effect of reduced body weight on muscle aerobic capacity in patients with COPD.

Authors:  P Palange; S Forte; P Onorati; V Paravati; F Manfredi; P Serra; S Carlone
Journal:  Chest       Date:  1998-07       Impact factor: 9.410

View more
  3 in total

Review 1.  Understanding cancer-induced cachexia: imaging the flame and its fuel.

Authors:  Marie-France Penet; Paul T Winnard; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Curr Opin Support Palliat Care       Date:  2011-12       Impact factor: 2.302

2.  The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease.

Authors:  Sheryl F Vondracek; Norbert F Voelkel; Michael T McDermott; Connie Valdez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-07-20

3.  Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores.

Authors:  Wen-Te Liu; Han-Pin Kuo; Tien-Hua Liao; Ling-Ling Chiang; Li-Fei Chen; Min-Fang Hsu; Hsiao-Chi Chuang; Kang-Yun Lee; Chien-Da Huang; Shu-Chuan Ho
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.